Merck secured FDA approval for Keytruda Qlex, an injectable formulation of its blockbuster cancer immunotherapy Keytruda. The new injectable version shortens administration time from 30 minutes to mere minutes while maintaining comparable efficacy to the original infusion, as demonstrated in the pivotal clinical trials. This approval marks a critical step in improving patient convenience and expanding immunotherapy accessibility in oncology treatment settings.